VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2021 | Post-transplant relapse in Ph+ ALL

Allogeneic transplantation represents a cure for many patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ali Bazarbachi, MD, PhD, American University of Beirut-Medical Center, Beirut, Lebanon, highlights some of the treatment options for those who relapse post-transplant. Specifically mentioned is the withdrawal of immunosuppression, chemotherapy, Tyrosine kinase inhibitors (TKIs), donor lymphocyte infusion and second allogeneic transplantation. Prof. Bazarbachi goes on to highlight how monoclonal antibody and CAR-T therapies continue to improve outcomes. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter